Associations of pathway‐specific polygenic risk scores with clinical status and Alzheimer’s‐related biomarkers

The APOE gene represents the largest genetic risk factor in sporadic Alzheimer’s disease (AD), but there is a substantial polygenic component as well. Polygenic risk scores (PRS) represent a useful approach to summarize small effects across the genome but may obscure which pathways are affected. Variability across individuals at the genetic level may contribute to the extensive phenotypic heterogeneity of AD. Therefore, we calculated polygenic risk in multiple pathways associated with AD and examined its relationship with clinical status and AD biomarkers.